Adverum Biotechnologies

Recent Finacing

Series B

Recent Raise

$55M

Avalanche Biotechnologies is a clinical-stage biotech developing AAV-based gene therapies for retinal diseases using its proprietary BioFactory platform, advancing AVA-101 in Phase 2a for wet age-related macular degeneration.

Founded 2006

California, United States

101-250

Publicly Traded

adverum.com

Highlights

Focus Areas

Biotechnology

Pharmaceutical

Therapeutics

Recent Investors

Financials

$55M

Total Raised

1

Funding round

7

Investors